Marshall Wace LLP Sells 253,529 Shares of Annexon, Inc. (NASDAQ:ANNX)

Marshall Wace LLP lessened its holdings in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 86.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 38,845 shares of the company's stock after selling 253,529 shares during the period. Marshall Wace LLP's holdings in Annexon were worth $199,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ANNX. Barclays PLC grew its position in shares of Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company's stock valued at $1,052,000 after purchasing an additional 120,789 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Annexon by 16.0% during the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company's stock valued at $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in shares of Annexon by 65.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 429,584 shares of the company's stock valued at $2,204,000 after purchasing an additional 170,180 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Annexon during the fourth quarter valued at about $116,000. Finally, Rhumbline Advisers grew its position in shares of Annexon by 4.3% during the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after purchasing an additional 5,854 shares in the last quarter.

Annexon Trading Down 5.6%

Shares of NASDAQ:ANNX traded down $0.10 during trading on Friday, reaching $1.61. The company's stock had a trading volume of 1,210,735 shares, compared to its average volume of 1,788,865. Annexon, Inc. has a 12 month low of $1.29 and a 12 month high of $7.85. The firm's 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $3.82. The stock has a market capitalization of $176.09 million, a PE ratio of -1.53 and a beta of 1.24.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). Research analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.